Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices 35291 

A. Federal Reserve Bank of Atlanta 

(Erien O. Terry, Assistant Vice 

President) 1000 Peachtree Street NE, 

Atlanta, Georgia 30309. Comments can 

also be sent electronically to 

Applications.Comments@atl.frb.org: 

1. The Sue Soileau Trust, Steven G. 

Durio and Anthony Kip Bertrand, as cotrustees, The David C. Brignac, Jr. Trust, 

Steven G. Durio, as trustee, all of 

Lafayette, Louisiana; and the 

Washington State Bancshares Employee 

Stock Ownership Plan (ESOP), 

Washington Louisiana, Steven G. Durio, 

as trustee of the ESOP, as a group acting 

in concert to acquire additional voting 

shares of Washington State Bancshares, 

Inc. and thereby indirectly acquire 

additional voting shares of Washington 

State Bank, both of Washington, 

Louisiana. 

Board of Governors of the Federal Reserve 

System, June 28, 2021. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2021–14153 Filed 7–1–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Advisory Board on 

Radiation and Worker Health for the 

Energy Employees Occupational 

Illness Compensation Program Act of 

2000 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) is seeking 

nominations for membership on the 

Advisory Board on Radiation and 

Worker Health (ABRWH) for the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000 

(EEOICPA). The ABRWH consists of not 

more than 20 members appointed by the 

President of the United States, and shall 

reflect a balance of scientific, medical, 

and worker perspectives. Nominations 

are being sought for individuals who 

have expertise and qualifications 

necessary to contribute to the 

accomplishments of the ABRWH’s 

objectives. Nominees will be appointed 

based on their demonstrated 

qualifications, professional experience, 

and knowledge of issues the ABRWH 

may be asked to consider. Federal 

employees will not be considered for 

membership. 

DATES: Nominations for individuals to 

serve on the ABRWH must be submitted 

(postmarked, if sending by mail; 

submitted electronically; or received, if 

hand delivered) no later than August 2, 

2021. Packages received after this time 

will not be considered. 

ADDRESSES: Nominations may be 

submitted, including attachments, by 

any of the following methods below: 

• Electronically: Email: 

(recommended) to Nancy Adams, dcas@

cdc.gov (specify in the email subject 

line, ‘‘Advisory Board on Radiation and 

Worker Health Nomination’’); or 

• Mail: Express Delivery, hand 

delivery messenger, or courier service: 

Submit one copy of all required 

documents to the following address: 

Nancy Adams, ABRWH, Office of the 

Director, National Institute of 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 395 

E Street SW, Suite 9200, Patriots Plaza, 

Washington, DC 20201. 

Follow-up communications with 

nominees may occur as necessary 

throughout the process. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Adams, National Institute for 

Occupational Safety and Health 

(NIOSH); Telephone: (540) 431–8024; 

Email: dcas@cdc.gov (Specify in the 

email subject line, ‘‘Advisory Board on 

Radiation and Worker Health 

Nomination’’). 

SUPPLEMENTARY INFORMATION: The 

Centers for Disease Control and 

Prevention (CDC) invites interested 

parties to submit nominations for 

individuals to serve on the ABRWH for 

the Energy Employees Occupational 

Illness Compensation Program Act of 

2000. The ABRWH was established 

pursuant to Section 3624 of Public Law 

106–398, and Section 4 of Executive 

Order 13179, ‘‘Providing Compensation 

to America’s Nuclear Weapons 

Workers,’’ dated December 7, 2000. The 

ABRWH is governed by the provisions 

of the Federal Advisory Committee Act, 

Public Law 92–463, as amended (5 

U.S.C. app. 2), which sets forth 

standards for the formation and use of 

advisory committees. The statutory 

authority for the ABRWH is codified at 

42 U.S.C. 7384o. The ABRWH currently 

operates under Executive Order 13889, 

dated September 27, 2019. 

Section 4(b) of Executive Order 13179 

establishes that the ABRWH shall 

provide advice to the Secretary, HHS on 

(1) the development of guidelines to 

assess the likelihood that an individual 

with cancer sustained the cancer in the 

performance of duty at a Department of 

Energy (DOE) or an Atomic Weapons 

Employer (AWE) facility, and methods 

for arriving at and providing reasonable 

estimates of the radiation doses received 

by individuals applying for assistance 

under this program for whom there are 

inadequate records of radiation 

exposure; (2) the scientific validity and 

quality of dose reconstruction efforts 

performed for purposes of the 

compensation program; and (3) upon 

request by the Secretary, HHS, whether 

there is a class of employees at any DOE 

or AWE facility who were exposed to 

radiation but for whom it is not feasible 

to estimate their radiation dose, and on 

whether there is reasonable likelihood 

that such radiation dose may have 

endangered the health of members of 

the class. More information on the 

ABRWH is available at https://

www.cdc.gov/niosh/ocas/ocasadv.html. 

As required by 42 U.S.C. 7384o(a)(2), 

the President shall make appointments 

to the Board in consultation with 

organizations with expertise on worker 

health issues in order to ensure that the 

membership of the Board reflects a 

balance of scientific, medical, and 

worker perspectives. The U.S. 

Department of Health and Human 

Services (HHS) policy stipulates that 

committee membership shall be made 

without discrimination on the basis of 

race, color, sex, religion, ethnicity, age, 

disability, gender, sexual orientation, 

gender identity, HIV status, genetic 

information, cultural, religious, or 

socioeconomic status. Minorities, 

women, and people with disability are 

encouraged to submit their nomination. 

Nominees must be U.S. citizens, and 

cannot be full-time employees of the 

U.S. government. Current participation 

on Federal workgroups or prior 

experience serving on a Federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. ABRWH 

members are Special Government 

Employees (SGEs), requiring the filing 

of financial disclosure reports, and they 

serve with compensation and may 

receive reimbursement for travel 

expenses for their attendance at 

ABRWH meetings, including per diem 

in lieu of subsistence, as authorized by 

the Federal travel regulations. The 

activities of the ABRWH may 

necessitate its members to obtain a topsecret security clearance. 

HHS may consider representation of a 

nominee’s knowledge, experience, and 

expertise in the fields of health physics, 

industrial hygiene, toxicology, 

epidemiology, occupational medicine, 

or the worker perspective in the nuclear 

facilities spanning the operationally and 

geographically diverse DOE and AWE 


lotter on DSK11XQN23PROD with NOTICES1
35292 Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices 

facilities covered by the EEOICPA 

programs; or familiarity, experience, or 

history of participation with the 

EEOICPA program. Any interested 

person or organization may nominate 

one or more individuals for 

membership. Interested persons are also 

invited and encouraged to submit 

statements in support of nominees. 

The ABRWH consists of not more 

than 20 members appointed by the 

President of the United States. As 

required by 42 U.S.C. 7384o(a)(2), the 

President makes appointments to the 

ABRWH in consultation with 

organizations with expertise on worker 

health issues in order to ensure that the 

membership of the ABRWH reflects a 

balance of scientific, medical, and 

worker perspectives. As required by 42 

U.S.C. 7384o(a)(3), the President 

designates a Chair for the ABRWH from 

among its members. The authorizing 

statutory provision under 42 U.S.C. 

7384o and Section 4 of Executive Order 

13179 do not include a limit for terms 

of appointment for ABRWH members. 

Nomination Process: Any interested 

person or organization may nominate 

one or more qualified individuals for 

membership. If you would like to 

nominate an individual or yourself for 

appointment to the ABRWH, please 

submit the following information: 

• The nominee’s contact information 

(name, title, business address, business 

phone, fax number, and/or business 

email address) and current employment 

or position. 

• A copy of the nominee’s resume or 

curriculum vitae; category of 

membership (e.g., scientific, medical, 

and/or worker perspective) that the 

nominee represents; a summary of the 

background, experience, and 

qualifications that addresses the 

nominee’s suitability for the nominated 

membership category identified above. 

• Articles or other documents the 

nominee has authored that indicate the 

nominee’s knowledge, experience, and 

expertise in the fields of health physics, 

industrial hygiene, toxicology, 

epidemiology, occupational medicine, 

or the worker perspective in the nuclear 

facilities covered by the EEOICPA 

program; or familiarity, experience, or 

history of participation with the 

EEOICPA program. Nominations may be 

submitted by the candidate him or 

herself, or by the person/organization 

recommending the candidate. 

• At least one letter of 

recommendation from person(s) not 

employed by the U.S. Department of 

Health and Human Services. Candidates 

may submit letter(s) from current HHS 

employees if they wish, but at least one 

letter must be submitted by a person not 

employed by an HHS agency (e.g., CDC, 

NIH, FDA, etc.). 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–14204 Filed 7–1–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–0307] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Gonococcal 

Isolate Surveillance Project (GISP)’’ to 

the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on March 8, 2021 to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Gonococcal Isolate Surveillance 

Project—Revision—National Center for 

HIV/AIDS, Viral Hepatitis, STD, TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Gonococcal Isolate Surveillance 

Project (GISP) was created in 1986 to 

monitor trends in antimicrobial 

susceptibilities of Neisseria gonorrhoeae 

strains in the United States. GISP 

continues to be a collaboration between 

different branches of the CDC’s Division 

of STD Prevention, selected regional 

laboratories, and selected state/local 

public health departments and their 

associated STD specialty care clinics in 

the United States. National 

organizations, local jurisdictions and 

individuals use data collected in GISP 

to understand, monitor, and prevent 

further transmission of antibiotic 

resistant strains of N. gonorrhoeae. Data 

from GISP are used to establish a 

scientific basis for the selection of 

gonococcal therapies and to allow proactive changes to treatment guidelines 

before widespread resistance and 

failures of treatment occur. To increase 

capacity to detect and monitor resistant 

gonorrhea and to improve the specificity 

of GISP, this revision is being submitted 

to include collection of remnant nucleic 

acid amplification test (NAAT) 


lotter on DSK11XQN23PROD with NOTICES1